Furthermore, MYC target gene activation was observed to gradually decrease during ibrutinib treatment, with analysis conducted on 10,299 CLL cells before ibrutinib and 9,450 CLL cells during ibrutinib treatment across three different time points (Supplementary Figure S4c). This evidence concerns the gene MYC and B-cell chronic lymphocytic leukemia.